Peptidomimetic compounds as immunomodulators
AssigneeAurigene Discovery Technologies Limited
InventorsPottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
Claims11
A compound of Formula (I):
- wherein;
- R1 is hydrogen, —OR6, —OC(O)R6, halogen, cyano, or hydroxyalkyl;
- R1′ is hydrogen or alkyl;
- both Ra and Ra′ is hydrogen;
- or together represent an oxo (═O) group or a thioxo (═S) group;
- both Rb and Rb′ is hydrogen;
- or together represent an oxo (═O) group or a thioxo (═S) group;
- R2 and R3 independently are hydrogen, optionally substituted alkyl or optionally substituted acyl;
- R4 and R4′ independently are hydrogen, optionally substituted alkyl or optionally substituted acyl;
- R6 is hydrogen or optionally substituted alkyl;
- ‘n’ is an integer selected from 1 or 2;
- Rc is hydroxyl or amino;
- R5 is —C(═X)—Am1—R7;
- wherein, X is O or S;
- Am1 is an amino acid residue Ser, Asp, Ala, Ile, Phe, Trp, Glu, or Thr;
- wherein the amino acid residue is optionally substituted with an alkyl or an acyl group;
- R7 is an alpha carboxylic group of Am1 which is in free acid, ester or in amide form;
- wherein the amide nitrogen is optionally substituted with hydroxyl or amino;
- or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
A compound of a structure that is
- Compound
- No
- Structure
- 2.
- 3.
- 4.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.
- 42.
- 43.
- 44.
- 45.
- 46.
- 47.
- 48.
- 49.
- 50.
- 51.
- 52.
- 53.
- 54.
- 55.
- 56.
- 57.
- 58.
- 59.
- 60.
- 61.
- 62.
- 63.
- 64.
- 65.
- 66.
- 67.
- 68.
- 69.
- 70.
- 71.
- 72.
- 73.
- 74.
- 75.
- 76.
- 77.
- 78.
- 79.
- 80.
- 81.
- 82.
- 83.
- 84.
- 85.
- 86.
- 87.
- 88.
- 89.
- 90.
- 91.
- 92.
- 93.
- 94.
- 95.
- 96.
- 97.
- 98.
- 99.
- 100.
- 101.
- 102.
- 103.
- 104.
- 105.
- 106.
- 107.
- 108.
- 109.
- 110.
- 111.
- 112.
- 113.
- 114.
- 115.
- 116.
- or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.